Species |
Human |
Protein Construction |
FGF basic (Pro143-Ser288) Accession # P09038-4 |
|
Purity |
> 95% as determined by Bis-Tris PAGE |
Endotoxin Level |
Less than 0.02 EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized FGF basic, Human at 0.5 μg/ml (100 μl/Well) on the plate can bind Human Glypican 1, His Tag. Test result was comparable to standard batch. Measured in a cell proliferation assay using BALB/c 3T3 mouse embryonic fibroblasts. The ED50 for this effect is 0.1 0.6 ng/ml. Test result was comparable to standard batch. |
Expression System |
E.coli |
Theoretical Molecular Weight |
16.5 kDa |
Apparent Molecular Weight |
The protein has a predicted MW of 16.5 kDa same as Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. |
Synonyms |
bFGF; FGF basic; FGF2; FGF-2; FGF2AS; GFG1; HBGF-2; NUDT6; Prostatropin; BFGF; FGFB; FGFβ; HBGF2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.